Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Dr. Kayla Griffith, Breast Surgical Oncologist, and HCA HealthONE Rose—part of the HCA HealthONE network of 9 hospitals and 17 surgery centers...
Modular Medical (NASDAQ: MODD) has announced that the Institutional Review Board (IRB) has granted approval to conduct an in-house study of its next-generation Pivot insulin delivery system using insulin on people with...
Adaptimmune Therapeutics (OTC PINK: ADAPY) has announced changes to its board of directors (BOD) and leadership team effective November 14, 2025, following the voluntary delisting of the company’s American Depository...
Zynex (NASDAQ: ZYXI) has announced the engagement of financial advisory firm Province LLC, the appointment of Paul Aronzon to its board of directors, and the formation of a special committee. Mr. Paul Aronzon brings...
Profound Medical (NASDAQ: PROF; TSX: PRN) announced that total revenues for the third quarter of 2025 were $5.3 million, representing year-over-year revenue growth of 87%. The gross margin for the third quarter of 2025...
Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing, FDA-regulated Phase 1/2a clinical trial evaluating...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO system with closely held Getz Healthcare, a leading distributor of...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical...
Precision BioSciences (NASDAQ: DTIL) announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, to be delivered by Dr. Man-Fung Yuen, Chair...
Altimmune (NASDAQ: ALT) has announced publication of 4-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) in The...